NCT04821765

Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

A Phase II Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Squamous Cell Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Chemoradiotherapy（CRT） is the main treatment for esophageal cancer patients with recurrent desease，and checkpoint blockade (PD-1) have been shown to be effective in advanced esophageal cancer. Therefore, PD-1 combined with chemoradiotherapy （CRT）may further improve the efficacy and become a new method for the treatment of esophageal cancer.This study intends to conduct a single-arm, prospective clinical study, aiming to evaluate the safety and efficacy of PD-1 combined with chemoradiotherapy(CRT) in patients with oligometastatic esophageal squamous cell carcinoma.

Conditions

• Esophagus Cancer
• Chemoradiotherapy
• Oligometastatic Disease
• Immunotherapy

Interventions

Type	Name	Description
DRUG	PD-1 antibody	200mg, d1, q3W
RADIATION	Chemoradiation	50-60Gy (BED) was given (1.8-2 Gy or 3-4Gy once daily , 5 days a week
DRUG	Albumin-Bound Paclitaxel	150mg/m2, d1, q3W
DRUG	Cisplatin	75mg/m2, d1, q3W

Timeline

• Start date: 2020-10-01
• Primary completion: 2023-06-30
• Completion: 2024-12-31
• First posted: 2021-03-30
• Last updated: 2025-05-30

Locations

2 sites across 1 country: China